Comerica Bank Grows Position in Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX)

Comerica Bank increased its position in shares of Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX - Free Report) by 220.0% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 800,000 shares of the company's stock after acquiring an additional 550,000 shares during the quarter. Comerica Bank owned 0.36% of Lineage Cell Therapeutics worth $402,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in LCTX. Barclays PLC grew its position in Lineage Cell Therapeutics by 311.3% during the third quarter. Barclays PLC now owns 211,300 shares of the company's stock valued at $192,000 after purchasing an additional 159,924 shares in the last quarter. JPMorgan Chase & Co. grew its position in Lineage Cell Therapeutics by 13.9% during the third quarter. JPMorgan Chase & Co. now owns 677,162 shares of the company's stock valued at $613,000 after purchasing an additional 82,864 shares in the last quarter. SG Americas Securities LLC grew its position in Lineage Cell Therapeutics by 35.5% in the fourth quarter. SG Americas Securities LLC now owns 68,973 shares of the company's stock worth $35,000 after acquiring an additional 18,053 shares in the last quarter. Defender Capital LLC. grew its position in Lineage Cell Therapeutics by 19.2% in the fourth quarter. Defender Capital LLC. now owns 5,963,348 shares of the company's stock worth $2,997,000 after acquiring an additional 961,150 shares in the last quarter. Finally, Atria Wealth Solutions Inc. bought a new stake in Lineage Cell Therapeutics in the fourth quarter worth approximately $29,000. 62.47% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of research firms have recently commented on LCTX. HC Wainwright reiterated a "buy" rating and issued a $9.00 price objective on shares of Lineage Cell Therapeutics in a research note on Tuesday, March 11th. D. Boral Capital reaffirmed a "buy" rating and issued a $2.00 price target on shares of Lineage Cell Therapeutics in a research report on Tuesday, March 11th. Finally, B. Riley cut their price target on Lineage Cell Therapeutics from $4.00 to $3.00 and set a "buy" rating for the company in a report on Friday, March 14th. Five research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Lineage Cell Therapeutics presently has a consensus rating of "Buy" and an average price target of $4.20.

Lineage Cell Therapeutics Trading Up 7.4%

Lineage Cell Therapeutics stock traded up $0.03 during trading on Monday, hitting $0.50. 987,100 shares of the company were exchanged, compared to its average volume of 1,303,902. The business's 50 day moving average is $0.46 and its 200 day moving average is $0.63. Lineage Cell Therapeutics, Inc. has a 52 week low of $0.37 and a 52 week high of $1.15. The company has a market capitalization of $109.64 million, a P/E ratio of -4.15 and a beta of 1.21.

About Lineage Cell Therapeutics

Lineage Cell Therapeutics, Inc, a clinical-stage biotechnology company, develops novel cell therapies for unmet medical needs in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries; and VAC, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer.